Pemetrexed Induced Life-threatening Anaphylaxis.
| Autor: | Rajasurya V; Pulmonary Critical Care, Novant Health, Winston Salem, USA., Pyakuryal B; Internal Medicine, Nepal Medical College, Kathmandu, NPL., Gunasekaran K; Pulmonary Critical Care, Yale New Haven Health at Bridgeport Hospital, Bridgeport, USA., Sekar V; Internal Medicine, Bassett Medical Center, Cooperstown, USA., Dhakal P; Hematology and Oncology, University of Nebraska Medical Center, Omaha, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2019 Aug 29; Vol. 11 (8), pp. e5514. Date of Electronic Publication: 2019 Aug 29. |
| DOI: | 10.7759/cureus.5514 |
| Abstrakt: | Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Society for Clinical Oncology (ASCO) recommends platinum based regimens as the first-line of treatment for NSCLC. Pemetrexed, an antifolate agent, has been approved by the ASCO for the treatment of advanced non-squamous NSCLC and has been shown to be efficient for first-line, maintenance and second- or third-line treatment in this subgroup. It is administered intravenously over 10 minutes and is usually well tolerated with a very few side effects. There have been a few cases of anaphylaxis reported with pemetrexed use and most of the patients presented only with cutaneous manifestations. We present a patient with stage IV adenocarcinoma of the lung who developed a severe life threatening anaphylactic reaction requiring ventilatory support after administration of pemetrexed. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2019, Rajasurya et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|